Normalization of tumor vasculature by imiquimod: proposal for a new anticancer therapeutic indication for a TLR7 agonist
Abstract Imiquimod (IMQ), a drug from aminoquinoline group, is the toll-like receptor 7 (TLR7) agonist. It acts as an immunostimulant and radio-sensitizing agent. IMQ stimulates both innate and adaptive immune response. Despite studies conducted, there are no unambiguous data showing how IMQ affects...
Saved in:
Main Authors: | Jarosz-Biej Magdalena, Czapla Justyna, Ciepła Joanna, Smolarczyk Ryszard, Drzyzga Alina, Sprus-Lipka Dorota, Pilny Ewelina, Matuszczak Sybilla, Cichoń Tomasz |
---|---|
Format: | Article |
Language: | English |
Published: |
Springer
2025-02-01
|
Series: | Cancer Immunology, Immunotherapy |
Subjects: | |
Online Access: | https://doi.org/10.1007/s00262-025-03943-2 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pilot clinical trial of neoadjuvant toll-like receptor 7 agonist (Imiquimod) immunotherapy in early-stage oral squamous cell carcinoma
by: Angela J. Yoon, et al.
Published: (2025-01-01) -
Stevens-Johnson Syndrome and Erythema Multiforme Induced by Imiquimod 5% Cream
by: Ilaria Salvi, et al.
Published: (2025-01-01) -
Conglomerated Imiquimod and Metronidazole Incorporated Biodegradable Nanofibrous Mats for Potential Therapy of Cervical Cancer
by: Chen YP, et al.
Published: (2025-01-01) -
Comparative Efficacy and Tolerability of Imiquimod 3.75% Cream vs 5-Fluorouracil 4% cream in the Treatment of Actinic Keratosis: A Split-Face Study
by: Cesare Ariasi, et al.
Published: (2025-01-01) -
Evaluation of three novel antigens and costimulatory agents for improvement of M. Tuberculosis specific interferon gamma release assays
by: Sandra Schwarzlose-Schwarck, et al.
Published: (2025-02-01)